Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer
| Autor: | Aya Sakai, Ikuya Miki, Takuya Mimura, Saeko Kushida, Masahiro Tsuda, Yoshinobu Yamamoto, Naoki Takegawa, Hidetaka Tsumura, Nagahiro Tokuyama, Michiko Nishikawa |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Cancer Treatment Biochemistry Metastasis Prognostic score Antineoplastic Agents Immunological 0302 clinical medicine Basic Cancer Research Ascites Medicine and Health Sciences Aged 80 and over Multidisciplinary Medical record Middle Aged Esophageal cancer Advanced gastric cancer C-Reactive Proteins Prognosis Progression-Free Survival C-Reactive Protein Nivolumab Oncology Nephrology Research Design Renal Cancer 030220 oncology & carcinogenesis Medicine Female medicine.symptom Research Article Adult medicine.medical_specialty Esophageal Cancer Science Gastroenterology and Hepatology 03 medical and health sciences Stomach Neoplasms Internal medicine Gastrointestinal Tumors Biomarkers Tumor medicine Humans Serum Albumin Aged Neoplasm Staging Retrospective Studies business.industry Cancers and Neoplasms Biology and Life Sciences Proteins Cancer medicine.disease Gastric Cancer 030104 developmental biology business |
| Zdroj: | PLoS ONE, Vol 16, Iss 2, p e0247645 (2021) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | In Japan, South Korea, and Taiwan, nivolumab might provide overall survival benefits for patients with advanced gastric cancer. However, it is effective only in a limited number of patients. The Glasgow prognostic score is an indicator of the systematic inflammatory response and nutritional status. This study aimed to investigate the ability of the Glasgow prognostic score and other markers to predict the outcomes of patients treated with nivolumab. We reviewed the medical records of patients treated for advanced gastric cancer and who received nivolumab between February 2015 and June 2019 at Hyogo Cancer Center. The patients were categorized into two groups according to their Glasgow prognostic scores. Overall, 53.3% and 46.7% of the patients were assigned to groups with Glasgow prognostic scores of 0 and 1/2, respectively. The median durations of progression-free and overall survival of the participants were 2.3 and 5.7 months, respectively. The patients with a Glasgow prognostic score of 0 had significantly higher median overall survival than those with scores of 1 or 2 (16.4 vs. 4.2 months; p = 0.0006). This observation suggests that a pretreatment Glasgow prognostic score of 0 is associated with better outcomes, and this scoring system may be used as a predictor of outcomes in patients with advanced gastric cancer treated with nivolumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|